AUPH — Aurinia Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.12bn
- $831.93m
- $235.13m
- 87
- 26
- 93
- 77
Annual income statement for Aurinia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 50.1 | 45.6 | 134 | 176 | 235 |
| Cost of Revenue | |||||
| Gross Profit | — | 44.5 | 128 | 161 | 207 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 154 | 226 | 246 | 267 | 240 |
| Operating Profit | -104 | -181 | -111 | -91.7 | -4.69 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -103 | -180 | -106 | -77.5 | 7.45 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -103 | -181 | -108 | -78 | 5.75 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -103 | -181 | -108 | -78 | 5.75 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -103 | -181 | -108 | -78 | 5.75 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.867 | -1.4 | -0.762 | -0.545 | 0.161 |